Updated on 2024/10/07

Information

 

写真a

 
HIRABAYASHI SHIGEKI
 
Organization
Faculty of Medical Sciences Department of Clinical Medicine Assistant Professor
Faculty of Medical Sciences Research Center for Precision Medicine（Concurrent）
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
External link

Research Areas

  • Life Science / Hematology and medical oncology

  • Life Science / System genome science

Degree

  • Bachelor (Pharmacy) (Nagoya City University)

  • Bachelor (Medicine) (Niigata University)

  • Doctor (Medicine) (Kyoto University)

Research History

  • Kyushu University Faculty of Medical Sciences Assistant Professor

    2022.3 - Present

    　 More details

  • Kyushu University Faculty of Medical Sciences

    2021.4 - 2022.2

    　 More details

Research Interests・Research Keywords

  • Research theme：Searching for new cancer treatment targets based on large-scale genomics and functional screening

    Keyword：CRISPR screening

    Research period： 2022.4 - 2022.6

Awards

  • ふくおか「臨床医学研究賞」

    2022.3  

    　More details

    DDX41変異を有する骨髄系腫瘍の遺伝子発現制御機構の解明とその治療法の開発を行う

  • ふくおか「臨床医学研究賞」

    2022  

    　More details

  • 日本臨床腫瘍学会奨励賞

    2021.2  

  • 日本血液学会奨励賞

    2020.10  

  • 有壬記念学術奨励賞

    2020.6  

  • 理研梅峰賞

    2020.3  

▼display all

Papers

  • Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph+ALL: A retrospective nationwide study Reviewed

    Shigeki Hirabayashi, Tadakazu Kondo, Satoshi Nishiwaki, Shuichi Mizuta, Noriko Doki, Takahiro Fukuda, Naoyuki Uchida, Yukiyasu Ozawa, Yoshinobu Kanda, Ryota Imanaka, Satoshi Takahashi, Jun Ishikawa, Shingo Yano, Hirohisa Nakamae, Tetsuya Eto, Takafumi Kimura, Junji Tanaka, Tatsuo Ichinohe, Yoshiko Atsuta, Shinichi Kako

    American Journal of Hematology   2023.7

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/ajh.27041

    researchmap

  • Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT Reviewed

    2021.6

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/cam4.3920

  • APOBEC3B is preferentially expressed at the G2/M phase of cell cycle Reviewed

    Shigeki Hirabayashi, Kotaro Shirakawa, Yoshihito Horisawa, Tadahiko Matsumoto, Hiroyuki Matsui, Hiroyuki Yamazaki, Anamaria Daniela Sarca, Yasuhiro Kazuma, Ryosuke Nomura, Yoshinobu Konishi, Suguru Takeuchi, Emani Stanford, Hideya Kawaji, Yasuhiro Murakawa, Akifumi Takaori-Kondo

    Biochemical and Biophysical Research Communications   546   178 - 184   2021.3

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbrc.2021.02.008

  • NET-CAGE characterizes the dynamics and topology of human transcribed cis-regulatory elements Reviewed International journal

    Shigeki Hirabayashi, Shruti Bhagat, Yu Matsuki, Yujiro Takegami, Takuya Uehata, Ai Kanemaru, Masayoshi Itoh, Kotaro Shirakawa, Akifumi Takaori-Kondo, Osamu Takeuchi, Piero Carninci, Shintaro Katayama, Yoshihide Hayashizaki, Juha Kere, Hideya Kawaji, Yasuhiro Murakawa

    Nature Genetics   51 ( 9 )   1369 - 1379   2019.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41588-019-0485-9

  • Successful treatment of severe acute gastrointestinal graft-versus-host disease complicated by cytomegalovirus gastroenteritis with intra-arterial steroid infusion. Reviewed

    Hirabayashi S, Kondo T, Oka T, Akamatsu Y, Hishizawa M, Shibata T, Kitano T, Takaori-Kondo A

    Annals of hematology   2016.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00277-016-2686-y

  • Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Reviewed International journal

    Hirabayashi S, Kosugi S, Isobe Y, Nashimoto A, Oda I, Hayashi K, Miyashiro I, Tsujitani S, Kodera Y, Seto Y, Furukawa H, Ono H, Tanabe S, Akazawa K

    Annals of oncology : official journal of the European Society for Medical Oncology   25 ( 6 )   1179 - 84   2014.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/annonc/mdu125

  • The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating <i>MCL1</i> mRNA nuclear export in leukemia cells

    Terasaki, T; Semba, Y; Sasaki, K; Imanaga, H; Setoguchi, K; Yamauchi, T; Hirabayashi, S; Nakao, F; Akahane, K; Inukai, T; Sanda, T; Akashi, K; Maeda, T

    LEUKEMIA   38 ( 9 )   1918 - 1928   2024.7   （ ISSN:0887-6924 eISSN:1476-5551 ）

    　More details

    Language：English   Publisher：Leukemia  

    Selinexor, a first-in-class exportin1 (XPO1) inhibitor, is an attractive anti-tumor agent because of its unique mechanisms of action; however, its dose-dependent toxicity and lack of biomarkers preclude its wide use in clinical applications. To identify key molecules/pathways regulating selinexor sensitivity, we performed genome-wide CRISPR/Cas9 dropout screens using two B-ALL lines. We identified, for the first time, that paralogous DDX19A and DDX19B RNA helicases modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export. While single depletion of either DDX19A or DDX19B barely altered MCL1 protein levels, depletion of both significantly attenuated MCL1 mRNA nuclear export, reducing MCL1 protein levels. Importantly, combining selinexor treatment with depletion of either DDX19A or DDX19B markedly induced intrinsic apoptosis of leukemia cells, an effect rescued by MCL1 overexpression. Analysis of Depmap datasets indicated that a subset of T-ALL lines expresses minimal DDX19B mRNA levels. Moreover, we found that either selinexor treatment or DDX19A depletion effectively induced apoptosis of T-ALL lines expressing low DDX19B levels. We conclude that XPO1 and DDX19A/B coordinately regulate cellular MCL1 levels and propose that DDX19A/B could serve as biomarkers for selinexor treatment. Moreover, pharmacological targeting of DDX19 paralogs may represent a potential strategy to induce intrinsic apoptosis in leukemia cells.

    DOI： 10.1038/s41375-024-02343-2

    Web of Science

    Scopus

    PubMed

  • An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases.

    Oguchi A, Suzuki A, Komatsu S, Yoshitomi H, Bhagat S, Son R, Bonnal RJP, Kojima S, Koido M, Takeuchi K, Myouzen K, Inoue G, Hirai T, Sano H, ITEC Consortium Members

    Science (New York, N.Y.)   385 ( 6704 )   eadd8394   2024.7   （ ISSN:0036-8075 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1126/science.add8394

    Scopus

    PubMed

    researchmap

  • Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

    Terasaki, T; Semba, Y; Sasaki, K; Miyata, K; Yamauchi, T; Imanaga, H; Nakao, F; Hirabayashi, S; Nogami, J; Akahane, K; Inukai, T; Akashi, K; Maeda, T

    BLOOD   142   2023.11   （ ISSN:0006-4971 eISSN:1528-0020 ）

    　More details

  • Identification of Novel Transcripts and Potential Therapeutic Targets for Acute Leukemia

    Wada, F; Kato, S; Bhagat, S; Hirabayashi, S; Son, R; Oguchi, A; Takeuchi, K; Sekito, S; Hirai, T; Zhang, ZW; Horisawa, Y; Iwasaki, M; Takeda, J; Kanda, J; Sakamoto, T; Shirakawa, K; Takaori-Kondo, A; Murakawa, Y

    BLOOD   142   2023.11   （ ISSN:0006-4971 eISSN:1528-0020 ）

    　More details

  • Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance. Reviewed International journal

    Nakao F, Setoguchi K, Semba Y, Yamauchi T, Nogami J, Sasaki K, Imanaga H, Terasaki T, Miyazaki M, Hirabayashi S, Miyawaki K, Kikushige Y, Masuda T, Akashi K, Maeda T.

    Leukemia   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41375-023-01879-z

  • Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance. International journal

    Fumihiko Nakao, Kiyoko Setoguchi, Yuichiro Semba, Takuji Yamauchi, Jumpei Nogami, Kensuke Sasaki, Hiroshi Imanaga, Tatsuya Terasaki, Manaka Miyazaki, Shigeki Hirabayashi, Kohta Miyawaki, Yoshikane Kikushige, Takeshi Masuda, Koichi Akashi, Takahiro Maeda

    Leukemia   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41375-023-01879-z

  • HTLV-1 bZIP factor impairs DNA mismatch repair system. International journal

    Maki Sakurada-Aono, Takashi Sakamoto, Masayuki Kobayashi, Yoko Takiuchi, Fumie Iwai, Kohei Tada, Hiroyuki Sasanuma, Shigeki Hirabayashi, Yasuhiro Murakawa, Kotaro Shirakawa, Chihiro Sakamoto, Keisuke Shindo, Jun-Ichirou Yasunaga, Masao Matsuoka, Yves Pommier, Shunichi Takeda, Akifumi Takaori-Kondo

    Biochemical and biophysical research communications   657   43 - 49   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Adult T-cell leukemia (ATL) is a peripheral T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). Microsatellite instability (MSI) has been observed in ATL cells. Although MSI results from impaired mismatch repair (MMR) pathway, no null mutations in the genes encoding MMR factors are detectable in ATL cells. Thus, it is unclear whether or not impairment of MMR causes the MSI in ATL cells. HTLV-1 bZIP factor (HBZ) protein interacts with numerous host transcription factors and significantly contributes to disease pathogenesis and progression. Here we investigated the effect of HBZ on MMR in normal cells. The ectopic expression of HBZ in MMR-proficient cells induced MSI, and also suppressed the expression of several MMR factors. We then hypothesized that the HBZ compromises MMR by interfering with a transcription factor, nuclear respiratory factor 1 (NRF-1), and identified the consensus NRF-1 binding site at the promoter of the gene encoding MutS homologue 2 (MSH2), an essential MMR factor. The luciferase reporter assay revealed that NRF-1 overexpression enhanced MSH2 promoter activity, while co-expression of HBZ reversed this enhancement. These results supported the idea that HBZ suppresses the transcription of MSH2 by inhibiting NRF-1. Our data demonstrate that HBZ causes impaired MMR, and may imply a novel oncogenesis driven by HTLV-1.

    DOI： 10.1016/j.bbrc.2023.03.049

    PubMed

    researchmap

  • A genome-wide CRISPR-Cas9 screen reveals GATOR1 complex as a critical regulator of glucocorticoid sensitivity in B-ALL

    Imanaga, H; Hirabayashi, S; Akashi, K; Maeda, T

    CANCER SCIENCE   114   440 - 440   2023.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

    Imanaga, H; Semba, Y; Sasaki, K; Miyata, K; Yamauchi, T; Terasaki, T; Nakao, F; Hirabayashi, S; Nogami, J; Akashi, K; Maeda, T

    BLOOD   140   5979 - 5979   2022.11   （ ISSN:0006-4971 eISSN:1528-0020 ）

    　More details

  • Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.

    Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, Doki N, Fukuda T, Ozawa Y, Katayama Y, Kanda Y, Fukushima K, Matsuoka KI, Takada S, Yanada M

    Cytotherapy   24 ( 10 )   1013 - 1025   2022.6   （ ISSN:1465-3249 eISSN:1477-2566 ）

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jcyt.2022.05.009

    Web of Science

    PubMed

    researchmap

  • Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. International journal

    Kanda J, Hirabayashi S, Yokoyama H, Kawase T, Tanaka H, Uchida N, Taniguchi S, Takahashi S, Onizuka M, Tanaka M, Sugio Y, Eto T, Kanda Y, Kimura T, Japanese Society for Transplantation and Cellular Therapy's HLA Working Group

    Transplantation and cellular therapy   28 ( 7 )   398.e1-398.e9   2022.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The effect of single or multiple mismatches at each HLA locus on outcomes after cord blood transplantation (CBT) is controversial. We analyzed the effects of single or multiple HLA locus mismatches on the outcomes after single CBT using Japanese registry data from the Japan Society for Hematopoietic Cell Transplantation. Patients age ≥16 years with acute leukemia and myelodysplastic syndromes who underwent their first CBT between 2003 and 2017 (n = 4074) were included. The effect of the number of HLA locus mismatches (0, 1, or 2 for the HLA-A, -B, -C, and -DRB1 loci) on outcomes was analyzed after adjusting for other significant variables. The patient cohort had a median age of 54 years. The median total nucleated and CD34 cell doses were 2.6 × 107/kg and .8 × 105/kg, respectively. The number of CBTs with single or double mismatches were 2099 and 292, respectively, for the HLA-A locus, 2699 and 341 for the HLA-B locus, 2555 and 609 for the HLA-C locus, and 2593 and 571 for the HLA-DRB1 locus. Single and double HLA-DRB1 mismatches were associated with a higher risk of grade II-IV acute graft-versus-host disease (GVHD; single: hazard ratio [HR], 1.29, P < .001; double: HR, 1.49, P < .001; P for trend <.001). Single and double mismatches at HLA-DRB1 as well as single mismatches at HLA-A and HLA-B also were associated with grade III-IV acute GVHD. Single and double HLA-B mismatches and double HLA-DRB1 mismatches were associated with a high risk of nonrelapse mortality (NRM). On the other hand, double mismatches at HLA-A or HLA-DRB1 and single mismatches at HLA-B were associated with a lower risk of relapse. HLA-DRB1 double mismatch was associated with high risk of grade II-IV and grade III-IV acute GVHD and NRM but lower risk of relapse. Not only the locus mismatch, but also the number of mismatches, should be considered in cord blood unit selection.

    DOI： 10.1016/j.jtct.2022.05.005

    PubMed

    researchmap

  • Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia Reviewed International journal

    Shimomura, Yoshimitsu; Sobue, Tomotaka; Hirabayashi, Shigeki; Kondo, Tadakazu; Mizuno, Shohei; Kanda, Junya; Fujino, Takahiro; Kataoka, Keisuke; Uchida, Naoyuki; Eto, Tetsuya; Miyakoshi, Shigesaburo; Tanaka, Masatsugu; Kawakita, Toshiro; Yokoyama, Hisayuki; Doki, Noriko; Harada, Kaito; Wake, Atsushi; Ota, Shuichi; Takada, Satoru; Takahashi, Satoshi; Kimura, Takafumi; Onizuka, Makoto; Fukuda, Takahiro; Atsuta, Yoshiko; Yanada, Masamitsu

    LEUKEMIA   36 ( 4 )   1132 - 1138   2021.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41375-021-01474-0

  • Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia Reviewed

    Yoshimitsu Shimomura, Tomotaka Sobue, Shigeki Hirabayashi, Tadakazu Kondo, Shohei Mizuno, Junya Kanda, Takahiro Fujino, Keisuke Kataoka, Naoyuki Uchida, Tetsuya Eto, Shigesaburo Miyakoshi, Masatsugu Tanaka, Toshiro Kawakita, Hisayuki Yokoyama, Noriko Doki, Kaito Harada, Atsushi Wake, Shuichi Ota, Satoru Takada, Satoshi Takahashi, Takafumi Kimura, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada

    Leukemia   36 ( 4 )   1132 - 1138   2021.11

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41375-021-01474-0

  • The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Reviewed International journal

    Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Yano S

    Annals of hematology   100 ( 12 )   3017 - 3027   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00277-021-04661-2

  • Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type Reviewed International journal

    Konuma, Takaaki; Kanda, Junya; Kuwatsuka, Yachiyo; Yanada, Masamitsu; Kondo, Tadakazu; Hirabayashi, Shigeki; Kako, Shinichi; Akahoshi, Yu; Uchida, Naoyuki; Doki, Noriko; Ozawa, Yukiyasu; Tanaka, Masatsugu; Eto, Tetsuya; Sawa, Masashi; Yoshioka, Satoshi; Kimura, Takafumi; Kanda, Yoshinobu; Fukuda, Takahiro; Atsuta, Yoshiko; Kimura, Fumihiko

    CLINICAL CANCER RESEARCH   27 ( 17 )   4825 - 4835   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1158/1078-0432.CCR-20-4856

  • Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT Invited Reviewed International journal

    Hirabayashi, Shigeki; Uozumi, Ryuji; Kondo, Tadakazu; Arai, Yasuyuki; Kawata, Takahito; Uchida, Naoyuki; Marumo, Atsushi; Ikegame, Kazuhiro; Fukuda, Takahiro; Eto, Tetsuya; Tanaka, Masatsugu; Wake, Atsushi; Kanda, Junya; Kimura, Takafumi; Tabuchi, Ken; Ichinohe, Tatsuo; Atsuta, Yoshiko; Yanada, Masamitsu; Yano, Shingo

    CANCER MEDICINE   10 ( 13 )   4250 - 4268   2021.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/cam4.3920

  • Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Reviewed International journal

    Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Yanada M

    Bone marrow transplantation   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-021-01380-0

  • Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type Reviewed International journal

    Takaaki Konuma, Junya Kanda, Yachiyo Kuwatsuka, Masamitsu Yanada, Tadakazu Kondo, Shigeki Hirabayashi, Shinichi Kako, Yu Akahoshi, Naoyuki Uchida, Noriko Doki, Yukiyasu Ozawa, Masatsugu Tanaka, Tetsuya Eto, Masashi Sawa, Satoshi Yoshioka, Takafumi Kimura, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Fumihiko Kimura

    Clinical Cancer Research   27 ( 17 )   4825 - 4835   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1158/1078-0432.CCR-20-4856

  • Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy‐refractory or relapsed disease prior to allogeneic stem cell transplantation Reviewed International journal

    194 ( 2 )   403 - 413   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL). However, the outcomes in patients transplanted without complete remission (non-CR) have not yet been fully reported, and detailed analyses are required to identify subgroups in which optimal prognosis is expected and to optimize pre-transplant therapeutic strategies. Hence, we performed a multicentred retrospective cohort study including a total of 663 adult ALL patients transplanted at non-CR status; the median bone marrow (BM) blast counts at HSCT was 13·2&#37;, and 203 patients (30·6&#37;) were treated at primary induction failure status. The overall survival (OS) was 31·1&#37; at two years, and the multivariate analyses identified five prognostic risk factors, including older age (≥50 years), increased BM blasts (≥10&#37;), poor performance status, high haematopoietic cell transplantation (HCT)-comorbidity index, and relapsed disease status, among which BM blast was the most significantly related. A predictive scoring system composed of these risk factors clearly stratified OS (15·6-59·5&#37; at two years). In conclusion, this is the first large-scale study to analyze the correlation of patient characteristics with post-transplant prognosis in ALL transplanted at non-CR status. The importance of blast control before HSCT should be focused on for better patient prognosis.

    DOI： 10.1111/bjh.17646

  • Identification of candidate PAX2-regulated genes implicated in human kidney development. Reviewed

    Yamamura Y, Furuichi K, Murakawa Y, Hirabayashi S, Yoshihara M, Sako K, Kitajima S, Toyama T, Iwata Y, Sakai N, Hosomichi K, Murphy PM, Tajima A, Wada T

    Scientific reports   11 ( 1 )   2021.4

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-021-88743-1

  • APOBEC3B is preferentially expressed at the G2/M phase of cell cycle Invited Reviewed International journal

    Hirabayashi S, Shirakawa K, Horisawa Y, Matsumoto T, Matsui H, Yamazaki H, Sarca AD, Kazuma Y, Nomura R, Konishi Y, Takeuchi S, Stanford E, Kawaji H, Murakawa Y, Takaori-Kondo A

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   546   178 - 184   2021.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbrc.2021.02.008

  • CAGE-seq reveals that HIV-1 latent infection does not trigger unique cellular responses in a Jurkat T cell model. Reviewed

    Matsui H, Shirakawa K, Konishi Y, Hirabayashi S, Sarca AD, Fukuda H, Nomura R, Stanford E, Horisawa Y, Kazuma Y, Matsumoto T, Yamazaki H, Murakawa Y, Takaori-Kondo A

    Journal of virology   95 ( 8 )   2021.1

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/jvi.02394-20

  • Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2 Reviewed International journal

    Satoshi Nishiwaki, Yu Akahoshi, Shuichi Mizuta, Akihito Shinohara, Shigeki Hirabayashi, Yuma Noguchi, Takahiro Fukuda, Naoyuki Uchida, Masatsugu Tanaka, Makoto Onizuka, Yukiyasu Ozawa, Shuichi Ota, Souichi Shiratori, Yasushi Onishi, Yoshinobu Kanda, Masashi Sawa, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako

    Blood Advances   5 ( 2 )   584 - 592   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/bloodadvances.2020003536

  • The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Reviewed International journal

    Tachibana T, Najima Y, Akahoshi Y, Hirabayashi S, Harada K, Doki N, Uchida N, Fukuda T, Sawa M, Ogata M, Takada S, Tanaka M, Matsuhashi Y, Tanaka J, dummy-AUTHOR_name, Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation

    Annals of hematology   99 ( 10 )   2393 - 2404   2020.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00277-020-04212-1

  • NET-CAGE characterizes the dynamics and topology of human transcribed cis-regulatory elements Reviewed International journal

    Hirabayashi S, Bhagat S, Matsuki Y, Takegami Y, Takuya U, Kanemaru A, Itoh M, Shirakawa K, Takaori-Kondo A, Takeuchi O, Carninci P, Katayama S, Hayashizaki Y, Kere J, Kawaji H, Murakawa Y.

    NATURE GENETICS   51 ( 9 )   1369 - +   2019.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41588-019-0485-9

  • Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells Reviewed International journal

    Hiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, Shigeki Hirabayashi, Yasuhiro Murakawa, Masayuki Kobayashi, Anamaria Daniela Sarca, Yasuhiro Kazuma, Hiroyuki Matsui, Wataru Maruyama, Hirofumi Fukuda, Ryutaro Shirakawa, Keisuke Shindo, Masaki Ri, Shinsuke Iida, Akifumi Takaori-Kondo

    Scientific Reports   9 ( 1 )   7122 - 7122   2019.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-019-43575-y

  • HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. Reviewed International journal

    Takiuchi Y, Kobayashi M, Tada K, Iwai F, Sakurada M, Hirabayashi S, Nagata K, Shirakawa K, Shindo K, Yasunaga JI, Murakawa Y, Rajapakse V, Pommier Y, Takaori-Kondo A

    Scientific reports   7 ( 1 )   12849 - 12849   2017.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-017-12924-0

  • Gastric cancer treated by endoscopic submucosal dissection or endoscopic mucosal resection in Japan from 2004 through 2006: JGCA nationwide registry conducted in 2013. Reviewed

    Tanabe S, Hirabayashi S, Oda I, Ono H, Nashimoto A, Isobe Y, Miyashiro I, Tsujitani S, Seto Y, Fukagawa T, Nunobe S, Furukawa H, Kodera Y, Kaminishi M, Katai H

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   20 ( 5 )   834 - 842   2017.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10120-017-0699-4

  • Successful treatment of severe acute gastrointestinal graft-versus-host disease complicated by cytomegalovirus gastroenteritis with intra-arterial steroid infusion Invited Reviewed International journal

    Hirabayashi, Shigeki; Kondo, Tadakazu; Oka, Tomomi; Akamatsu, Yuri; Hishizawa, Masakatsu; Shibata, Toshiya; Kitano, Toshiyuki; Takaori-Kondo, Akifumi

    ANNALS OF HEMATOLOGY   95 ( 8 )   1373 - 1375   2016.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00277-016-2686-y

  • Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer Reviewed International journal

    Hirabayashi S, Kosugi S, Isobe Y, Nashimoto A, Oda I, Hayashi K, Miyashiro I, Tsujitani S, Kodera Y, Seto Y, Furukawa H, Ono H, Tanabe S, Kaminishi M, Nunobe S, Fukagawa T, Matsuo R, Nagai T, Katai H, Wakai T, Akazawa K.

    ANNALS OF ONCOLOGY   25 ( 6 )   1179 - 1184   2014.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/annonc/mdu125

▼display all

Presentations

MISC

  • 複数のHLA座不適合が単一臍帯血移植後の成績に与える影響 JSTCT HLA WG研究

    諫田 淳也, 平林 茂樹, 横山 寿行, 川瀬 孝和, 田中 秀則, 内田 直之, 谷口 修一, 高橋 聡, 鬼塚 真仁, 田中 正嗣, 杉尾 康浩, 衛藤 徹也, 神田 善伸, 木村 貴文, 一戸 辰夫, 熱田 由子, 森島 聡子

    2021.9

    　More details

    Language：Japanese  

  • miRNAの発現と疾患の関わり

    平林 茂樹, 廣瀬 直毅, Michiel de Hoon

    医学のあゆみ   2019.4

    　More details

    Language：Others  

  • Cap Analysis of Gene Expression

    2017.1

    　More details

    Language：Others  

    Cap Analysis of Gene Expression

Professional Memberships

  • 日本血液学会

  • 日本内科学会

  • 日本癌学会

  • 日本造血・免疫細胞療法学会

  • 日本バイオインフォマティクス学会

  • 日本臨床腫瘍学会

▼display all

Committee Memberships

  • 九州大学   医学部教育主任  

    2022 - Present   

    　 More details

    Committee type：Other

    researchmap

Other

  • OSCE認定評価者

    2023 - Present

    　More details

  • 日本造血・免疫細胞療法学会認定医

    2022 - Present

    　More details

  • 日本血液学会専門医

    2018 - Present

    　More details

  • 日本内科学会認定医

    2016 - Present

    　More details

Research Projects

  • 遺伝性血液腫瘍の変異が病態に及ぼす本質的な意義の解明

    Grant number：24K18518  2024 - 2025

    日本学術振興会  科学研究費助成事業  若手研究

    平林 茂樹

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    急性骨髄性白血病/ 骨髄異形成症候群(AML/MDS)の原因遺伝子として、ATP依存性RNAヘリカーゼであるDDX41が同定された。DDX41変異を有するAML/MDS患者は、胚細胞変異としてA500fs、D140fsのような機能喪失型の変異を有し、後天的にR525Hを主とした体細胞変異を対側アリルに獲得し、AML/MDSを発症することが多い。近年DDX41変異を有するAML/MDSの発症・維持機構に関して様々な知見が得られているが、まだ十二分ではない。本研究では、DDX41変異がAML/MDSに果たす役割を解明することを目的として研究を行う。

    CiNii Research

  • 遺伝性血液腫瘍の発症に関わる病的バリアントの網羅的な同定

    2023 - 2025

    日本医療研究開発機構

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • 遺伝性免疫不全疾患のVUSへの機能的アノテーションに資する網羅的CRISPR塩基編集法の開発

    2023 - 2025

    日本医療研究開発機構

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • KRAS標的治療の抵抗性に関与するKRAS変異の網羅的同定

    2023 - 2024

    日本医療研究開発機構

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • 大規模ゲノミクスと機能的スクリーニングに基づく新規がん治療標的の探索

    2022.6

  • 大規模ゲノミクスと機能的スクリーニングに基づく新規がん治療標的の探索

    Grant number：22K16323  2022 - 2023

    日本学術振興会  科学研究費助成事業  若手研究

    平林 茂樹

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    近年のゲノム解析の進展により、血液腫瘍・がんの発症・維持に関与する遺伝子異常が複数同定され、それらに対する分子標的薬が開発されてきた。しかし、腫瘍に多様なクローンが存在するために、一部のクローンを分子標的薬で駆逐しても治療抵抗性の他のクローンが増殖し、根治がしばしば困難である。それゆえ、今なお従来の化学療法が欠かせないものとなっている。したがって、本研究ではがん細胞と正常細胞の生存に必須な遺伝子を同定することで、重篤な有害事象を抑えながらも血液腫瘍を主とした多彩ながんに奏功する新規治療法の開発を目指す。

    CiNii Research

  • 大規模ゲノミクスと機能的スクリーニングに基づく新規がん治療標的の探索

    2022 - 2023

    日本学術振興会  科学研究費助成事業  若手研究

    　 More details

    Grant type：Scientific research funding

▼display all

Class subject

  • 生命の科学A

    2023.4 - 2023.9   First semester

  • 医学部実習講義

    2022.4 - 2022.9   First semester

Travel Abroad

  • 2012.4 - 2012.5

    Staying countory name 1：United States   Staying institution name 1：University of California, Davis

  • 2010.8 - 2010.11

    Staying countory name 1：United States   Staying institution name 1：University of Massachusetts

  • 2008.8 - 2008.9

    Staying countory name 1：Russian Federation   Staying institution name 1：Far Eastern State Medical University

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Internal Medicine / Hematology

Clinician qualification

  • Certifying physician

    The Japanese Society of Internal Medicine（JSIM）

  • Specialist

    The Japanese Society of Hematology

  • Certifying physician

    日本造血・免疫細胞療法学会

Year of medical license acquisition

  • 2013